Abbott AxSYM U.S. Presence May Give Firm Edge Over BNP Competitors
This article was originally published in The Gray Sheet
Executive Summary
Abbott will try to leverage its installed U.S. base of 5,000 AxSYM automated analyzers to gain a competitive advantage over Bayer Diagnostics as each firm prepares a 2003 launch of a B-type natriuretic peptide (BNP) test to help diagnose congestive heart failure
You may also be interested in...
Biosite BNP Test Reimbursed At $47 In Tentative Payment Determination
A higher reimbursement rate for Biosite's Triage B-type natriuretic peptide test under CMS' 2003 laboratory fee schedule may provide an incentive for cardiologists to use the test in the outpatient setting
Biosite BNP Test Reimbursed At $47 In Tentative Payment Determination
A higher reimbursement rate for Biosite's Triage B-type natriuretic peptide test under CMS' 2003 laboratory fee schedule may provide an incentive for cardiologists to use the test in the outpatient setting
To Cross-Walk Or Gap-Fill? CMS Ponders BNP Test Reimbursement Options
The new common procedural terminology (CPT) code covering BNP tests to diagnose congestive heart failure should be "cross-walked" to the vasopressin CPT, manufacturers asserted at a Centers for Medicare & Medicaid Services public meeting in Baltimore Aug. 5